spacer
home > ict > autumn 2012 > tight connections
PUBLICATIONS
International Clinical Trials

Tight Connections


Sarah Palit of Informa Life Sciences talks to ICT about the upcoming Partnerships in Clinical Trials (PCT) Europe event, held in Hamburg this November


ICT: PCT Europe is recognised as an international meeting place for decision makers in the clinical outsourcing industry. But what makes the event so special?

Sarah Palit: PCT is Europe’s leading industry update for all clinical development outsourcing professionals, attracting more than 1,000 attendees. It provides a practical and strategic look at how to improve the relationship between clinical sponsors and their service providers, with access to the largest expert speaker panel in Europe – over 150 presenters, including Vice Presidents, Directors and Heads of Clinical Outsourcing. This year, we have more than 70 brand new case studies, plus formal discussions and informal networking opportunities, which will allow delegates to question the expert faculty and gain ideas that can be implemented on returning to the office. Networking is a huge benefit for PCT Europe’s attendees; we have Europe’s largest clinical outsourcing exhibition ever with more than 130 service offering clinical trial solutions.

What new session tracks will be featured at this year’s show?

PCT 2012 offers eight break-out streams and six break-out symposia. New session tracks for 2012 include: strategically managing risk; tactics for efficient operational delivery; critical examination of strategic outsourcing models; planning and measuring project success; emerging markets – gaining quality for value in emerging economies; strategic relationship management and oversight; expert opinion track – update on key industry challenges; and outsourcing strategies for small and mid-size pharma and biotech. These exciting new streams include presentations on real life examples and real data, plus panel sessions, where the audience can join in with their viewpoints and questions.

PCT showcases an impressive range of speakers. Who should we look out for?

I would recommend looking out for Dave deBronkart ‘e-patient Dave’; who will be explaining how, as an empowered patient, he beat Stage 4 cancer by leading his own recovery, and the economic keynote talk from Joe Nellis, Professor of International Management Economics, on the competitive outlook for 2013 and beyond.

Emerging markets are playing an increasingly significant role in clinical outsourcing. Will PCT 2012 be covering this hot topic?

Yes, we’re delighted to announce our brand new stream: emerging markets – gaining quality for value in emerging economies. Delegates attending this stream will discover the real costs of running clinical trials in other locations. We’re very excited about our speaker Wim Leereveld, Founder and CEO of Access to Medicine Foundation. We’ll also have presentations focusing on China, ensuring data quality and global testing harmonisation in China, the MENA region and Asia-Pacific.

What makes Hamburg the ideal location to host PCT 2012?

We are very lucky that the PCT 2012 congress centre is located conveniently in the middle of Hamburg, yet only five miles from Hamburg International airport. Hamburg has a unique cultural life and the Hamburg State Opera House is the oldest public opera house in Germany. With more than 300 theatres, music venues, cabarets and a lively museum and gallery scene, Hamburg boasts a cultural calendar of world-class dimension. So if our delegates find the time around the busy PCT 2012 schedule to visit the city, we are sure they’ll have a fantastic time!

What plans are afoot for the 2013 meeting?

We are currently at the early stages of research, but we will use what we learn at the 2012 event, especially from what’s talked about during the discussion and debates. There’s currently a lot changing in the outsourcing industry, including a lot of buzz around the effect of private equity buying up CROs. How will this affect key stakeholders and how will it change the clinical outsourcing landscape? We will address what the key stakeholders really think about strategic partnerships. As always, we will focus on cutting edge clinical outsourcing topics, real-life case studies and practical experience from senior level clinical outsourcing experts.


 




Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Sarah Palit is a Conference Director at Informa Life Sciences. Sarah is responsible for researching the agenda and recruiting top level industry speakers for flagship event Partnerships in Clinical Trials Congress and Exhibition. In addition Sarah manages the clinical events portfolio, which includes Phase 1-2a clinical trials and the preclinical summit.
spacer
Sarah Palit
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

Clinical Innovation Partnerships

11-12 September 2019, Hotel Palace, Berlin

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement